NASDAQ:LPTX - Leap Therapeutics Stock Price, News, Headlines & Rumors Sign in or create an account to add this stock to your watchlist. Get Started $7.26 +0.34 (+4.91 %) (As of 08/14/2018 04:00 PM ET)Previous Close$6.92Today's Range$6.98 - $7.3052-Week Range$4.90 - $10.25Volume17,400 shsAverage Volume82,072 shsMarket Capitalization$106 millionP/E Ratio-2.19Dividend YieldN/ABeta-0.19 Company ProfileAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. The company's clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer. Its clinical stage programs also include TRX518, a monoclonal antibody, which is in clinical trial targeting the glucocorticoid-induced tumor necrosis factor-related receptor in patients with solid tumors. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was founded in 2011 and is based in Cambridge, Massachusetts. Receive LPTX News and Ratings via Email Sign-up to receive the latest news and ratings for LPTX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:LPTX CUSIPN/A Webwww.leaptx.com Phone617-714-0360 Debt Debt-to-Equity RatioN/A Current Ratio5.32 Quick Ratio5.32 Price-To-Earnings Trailing P/E Ratio-2.19 Forward P/E Ratio-3.26 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book Value$0.90 per share Price / Book8.07 Profitability EPS (Most Recent Fiscal Year)($3.31) Net Income$-29,720,000.00 Net MarginsN/A Return on Equity-203.23% Return on Assets-86.48% Miscellaneous Employees22 Outstanding Shares14,500,000Market Cap$106 million Leap Therapeutics (NASDAQ:LPTX) Frequently Asked Questions What is Leap Therapeutics' stock symbol? Leap Therapeutics trades on the NASDAQ under the ticker symbol "LPTX." How were Leap Therapeutics' earnings last quarter? Leap Therapeutics Inc (NASDAQ:LPTX) posted its quarterly earnings data on Wednesday, August, 8th. The company reported ($0.50) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.49) by $0.01. View Leap Therapeutics' Earnings History. When is Leap Therapeutics' next earnings date? Leap Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, November, 12th 2018. View Earnings Estimates for Leap Therapeutics. What price target have analysts set for LPTX? 1 analysts have issued 12-month target prices for Leap Therapeutics' stock. Their predictions range from $12.50 to $12.50. On average, they anticipate Leap Therapeutics' share price to reach $12.50 in the next twelve months. This suggests a possible upside of 72.2% from the stock's current price. View Analyst Price Targets for Leap Therapeutics. What is the consensus analysts' recommendation for Leap Therapeutics? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Leap Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Leap Therapeutics. What are Wall Street analysts saying about Leap Therapeutics stock? Here are some recent quotes from research analysts about Leap Therapeutics stock: 1. According to Zacks Investment Research, "Leap Therapeutics, Inc. is a biopharmaceutical company. It develops novel therapeutics for the treatment of cancer. Leap Therapeutics, Inc. is based in Cambridge, United States. " (7/26/2018) 2. HC Wainwright analysts commented, "Olga Smolentseva, Ph.D. – (646-975-6966) / [email protected] Initial DKN-01 Results Show Promise; Anti- GITR Combines Well With Chemo; Reiterate Buy Preclinical and clinical results highlights the effects of DKN-01 on the immune system. On April 16, Leap presented new results at the 2018 American Association for Cancer Research (AACR) Annual Conference that highlight the immunomodulatory effect of DKN-01 in preclinical tumor models. According to the latest results, DKN-01 is able to significantly alter the makeup of the tumor microenvironment (Exhibit 1), attract immune cells by inducing Cxcl10 expression (Exhibit 2), and improve the efficacy of PD-1 checkpoint inhibition (Exhibit 3)." (4/12/2018) Who are some of Leap Therapeutics' key competitors? Some companies that are related to Leap Therapeutics include ZEALAND PHARMA/S (ZEAL), ZIOPHARM Oncology (ZIOP), Dermira (DERM), Evelo Biosciences (EVLO), Syros Pharmaceuticals (SYRS), American Brivision (Holding) (ABVC), Xeris Pharmaceuticals (XERS), GTX (GTXI), Vital Therapies (VTL), MediciNova (MNOV), Keryx Biopharmaceuticals (KERX), Sinovac Biotech (SVA), Verrica Pharmaceuticals (VRCA), Concert Pharmaceuticals (CNCE) and Aquestive Therapeutics (AQST). Who are Leap Therapeutics' key executives? Leap Therapeutics' management team includes the folowing people: Dr. Christopher K. Mirabelli Ph.D., CEO, Pres & Chairman (Age 64)Mr. Douglas E. Onsi J.D., CFO, Gen. Counsel, Treasurer & Sec. (Age 49)Mr. Augustine J. Lawlor, Chief Operating Officer (Age 62)Dr. Cynthia A. Sirard, VP of Clinical Devel. Has Leap Therapeutics been receiving favorable news coverage? News stories about LPTX stock have trended somewhat positive recently, Accern Sentiment reports. The research group rates the sentiment of news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Leap Therapeutics earned a coverage optimism score of 0.17 on Accern's scale. They also assigned press coverage about the company an impact score of 48.17 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days. View Recent Headlines for Leap Therapeutics. Who are Leap Therapeutics' major shareholders? Leap Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include DAFNA Capital Management LLC (1.05%), Renaissance Technologies LLC (0.78%), Point72 Asset Management L.P. (0.52%), DRW Securities LLC (0.27%) and Creative Planning (0.11%). View Institutional Ownership Trends for Leap Therapeutics. Which institutional investors are selling Leap Therapeutics stock? LPTX stock was sold by a variety of institutional investors in the last quarter, including DAFNA Capital Management LLC. View Insider Buying and Selling for Leap Therapeutics. Which institutional investors are buying Leap Therapeutics stock? LPTX stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., DRW Securities LLC, Renaissance Technologies LLC and Creative Planning. View Insider Buying and Selling for Leap Therapeutics. How do I buy shares of Leap Therapeutics? Shares of LPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Leap Therapeutics' stock price today? One share of LPTX stock can currently be purchased for approximately $7.26. How big of a company is Leap Therapeutics? Leap Therapeutics has a market capitalization of $106 million. The company earns $-29,720,000.00 in net income (profit) each year or ($3.31) on an earnings per share basis. Leap Therapeutics employs 22 workers across the globe. How can I contact Leap Therapeutics? Leap Therapeutics' mailing address is 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE MA, 02141. The company can be reached via phone at 617-714-0360. MarketBeat Community Rating for Leap Therapeutics (NASDAQ LPTX)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 122 (Vote Outperform)Underperform Votes: 102 (Vote Underperform)Total Votes: 224MarketBeat's community ratings are surveys of what our community members think about Leap Therapeutics and other stocks. Vote "Outperform" if you believe LPTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LPTX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 8/14/2018 by MarketBeat.com StaffFeatured Article: How are Outstanding Shares Different from Authorized Shares?